These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 22538464)
1. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Tobinai K; Takahashi T; Akinaga S Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464 [TBL] [Abstract][Full Text] [Related]
2. Mogamulizumab for the treatment of T-cell lymphoma. Makita S; Tobinai K Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848 [TBL] [Abstract][Full Text] [Related]
3. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. Moore DC; Elmes JB; Shibu PA; Larck C; Park SI Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540 [No Abstract] [Full Text] [Related]
4. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. Winsett FT; Lewis DJ; Duvic M Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026 [TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310 [TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Remer M; Al-Shamkhani A; Glennie M; Johnson P Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334 [TBL] [Abstract][Full Text] [Related]
8. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073 [TBL] [Abstract][Full Text] [Related]
17. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108 [TBL] [Abstract][Full Text] [Related]
18. Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab. Furukawa M; Ikeda K; Ohkawara H; Saito S; Takahashi H; Ueda K; Matsumoto H; Hashimoto Y; Ohto H; Ogawa K; Takeishi Y Int J Hematol; 2015 Oct; 102(4):498-505. PubMed ID: 25975265 [TBL] [Abstract][Full Text] [Related]
19. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo. Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Utsunomiya A; Choi I; Chihara D; Seto M Cancer Sci; 2015 Apr; 106(4):344-51. PubMed ID: 25613789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]